Industry / Spain

Spain Wary Over Biogenerics

November 2007 | Industry News

Printable version
Email
Bookmark

Spain's Ministry of Health (MoH) is reportedly hesitant to promote biosimilars - generic copies of biotechnology drugs - due to concerns that they do not have bioequivalency to the originator products.

To read the full article, please sign in or take a free trial.

Related Insight Articles

Generic Medicines Industry Association Puts Forward Recommendations To Push Market Sector

Industry / Spain Highlighting Spain as having one of the lowest levels of generic medicines uptake in Europe, the country's generic medicine industry association, AESEG, has put forward key recommendations to stimulate...

October 2009

Government To Maintain 4% Tax Rate On Medicines

Industry / Spain With the aim of increasing government revenues (to cover the growth in public sector spending as a recession grips Spain) and decrease its budget deficit (forecast to equal to 8.1% of GDP in 2010), the...

October 2009

New Distributor Margins Announced

Industry / Spain A recently published Royal Decree has set out new regulations for Spain's pharmaceutical supply chain. The decree, which replaces the two published in 1997, denotes the maximum margins that can be applied...

July 2008

New Distributor Margins Announced

July 2008

Zeltia To Float Unit

Industry / Spain Meanwhile, a public listing should prove a boon to the Spanish pharmaceutical industry and could result in similar action for a spate of other drug firms. In June 2007, leading indigenous player

December 2007